secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2024-06-11T23:59:59+00:00
Accession:  0001193125-24-158461
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Atara shareholders approve reverse stock split (1:4–1:30) and 2024 Equity Incentive Plan
--------------------------------------------------------------------------------

- Reverse stock split approved at board's discretion (ratio 1-for-4 to 1-for-30), board may abandon.
- 2024 Equity Incentive Plan approved: 53.96M for, 17.0M against, 24.84M broker non-votes.
- Automatic annual increase to 2024 Equity Incentive Plan rejected: 26.63M for, 44.29M against.
- Ratified Deloitte & Touche as auditors for FY2024: 89.69M for, 6.08M against.
- Two directors elected: William K. Heiden and Ameet Mallik, each with >64M votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312524158461/0001193125-24-158461-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312524158461/d741804d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-158461

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer